FINWIRES · TerminalLIVE
FINWIRES

Tokyo Century's Full-Year Net Income Jumps 31%

By

Tokyo Century's (TYO:8439) net income attributable to owners of the parent surged 31% to 111.3 billion yen for the fiscal year ended March 31 from 85.3 billion yen a year earlier.

The finance service company's earnings per share increased to 227.06 yen from 173.77 yen a year ago, according to a Tokyo bourse filing on Monday.

Revenues climbed 6.5% to 1.458 trillion yen from 1.369 trillion yen in the prior year.

In a separate disclosure, Tokyo Century raised its final dividend to 44 yen per share, from 36 yen per share, payable from June 26.

For the fiscal year ending March 31, 2027, the company expects attributable profit of 123 billion yen, and basic EPS of 251.66 yen.

Tokyo Century plans to pay interim and year-end dividends of 45.00 yen per share, each, for the year, which is higher than the amount paid in the year-ago period.

Related Articles

Asia

Shenzhen LDROBOT Soars 103% in Hong Kong Trading Debut

Shenzhen LDROBOT's (HKG:1236) shares opened 102.9% above their initial public offering price in a stellar Hong Kong debut on Monday morning.The Chinese robotics company opened at HK$53.50 per share, well above the offer price of HK$26.36.

HKG:1236
Asia

Concord Healthcare to Issue HK$68 Million Convertible Bonds to CSPC Pharma Unit

Concord Healthcare (HKG:2453) agreed to issue HK$68 million of convertible bonds to a unit of CSPC Pharmaceutical (HKG:1093), according to a Monday Hong Kong bourse filing.The oncology healthcare service provider said Dragon Merit will subscribe to the 2% convertible bonds due in April 2027.The bonds are convertible into as many as 40 million Hong Kong-listed shares at an initial conversion price of HK$1.70 per share, representing a premium of about 14.1% to the stock's last closing price.Net proceeds of about HK$63.1 million will mainly be used to repay loans and supplement working capital.Concord Healthcare said the investment is expected to deepen cooperation with CSPC Pharmaceutical in the oncology healthcare sector.

HKG:1093HKG:2453
Asia

Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%

Alterity Therapeutics (ASX:ATH) said findings of a study published in the NeuroImage journal support quantitative susceptibility mapping as an objective imaging biomarker to facilitate the earlier diagnosis of multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.Alterity is advancing its ATH434 lead candidate into a phase three program for multiple system atrophy, a neurodegenerative disease that leads to the failure of the autonomic nervous system and impaired movement.The company said it used quantitative susceptibility mapping in a phase two trial in which ATH434 helped improve diagnostic accuracy and provided "objective evidence of target engagement."The peer-reviewed publication validates the company's approach and "reinforces the role of [quantitative susceptibility mapping] as a biomarker for iron-modulating therapies in MSA," Alterity CEO David Stamler said.The company's shares fell 9% in recent Monday trade.

ASX:ATH